This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Startup Springboard in partnership with BIO-Europe Spring®
March 18, 2021
Delivered DigitallyCentral European Time

Adjuvant Genomics


Adjuvant Genomics combines genetic analysis and computational biology that can predetermine the success of adjuvant chemotherapy in Non-Small-Cell Lung Cancer patients.
 ~50% of NSCLC patients fail chemotherapy. This results in undue burden on the health care system and negative patient outcomes due to the effects of chemo. Adjuvant aims to prevent any patient that will not benefit from chemotherapy from receiving it.
A simple diagnostic test, sent through our proprietary amplification and screening protocol, and combined with artificial intelligence algorithms, provides the answer.